316 related articles for article (PubMed ID: 21889343)
21. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.
Bieliauskas AV; Weerasinghe SV; Pflum MK
Bioorg Med Chem Lett; 2007 Apr; 17(8):2216-9. PubMed ID: 17307359
[TBL] [Abstract][Full Text] [Related]
22. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
24. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Oanh DT; Hai HV; Park SH; Kim HJ; Han BW; Kim HS; Hong JT; Han SB; Hue VT; Nam NH
Bioorg Med Chem Lett; 2011 Dec; 21(24):7509-12. PubMed ID: 22036991
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
26. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
[TBL] [Abstract][Full Text] [Related]
27. Isoform-selective histone deacetylase inhibitors.
Bieliauskas AV; Pflum MK
Chem Soc Rev; 2008 Jul; 37(7):1402-13. PubMed ID: 18568166
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide.
Canzoneri JC; Chen PC; Oyelere AK
Bioorg Med Chem Lett; 2009 Dec; 19(23):6588-90. PubMed ID: 19854643
[TBL] [Abstract][Full Text] [Related]
29. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
Thaler F; Mercurio C
ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
[TBL] [Abstract][Full Text] [Related]
30. 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
Huong TT; Dung do TM; Oanh DT; Lan TT; Dung PT; Loi VD; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB; Nam NH
Med Chem; 2015; 11(3):296-304. PubMed ID: 25256241
[TBL] [Abstract][Full Text] [Related]
31. Structural biasing elements for in-cell histone deacetylase paralog selectivity.
Wong JC; Hong R; Schreiber SL
J Am Chem Soc; 2003 May; 125(19):5586-7. PubMed ID: 12733869
[TBL] [Abstract][Full Text] [Related]
32. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
33. An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors.
Shahidul Islam M; Nurul Islam M; Ashraful Hoque M; Nishino N; Kato T; Kim HJ; Ito A; Yoshida M
Bioorg Chem; 2015 Apr; 59():145-50. PubMed ID: 25797804
[TBL] [Abstract][Full Text] [Related]
34. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
35. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
Guerrant W; Patil V; Canzoneri JC; Oyelere AK
J Med Chem; 2012 Feb; 55(4):1465-77. PubMed ID: 22260166
[TBL] [Abstract][Full Text] [Related]
36. Melatonin-vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat.
Helmi YY; Papenkordt N; Rennar G; Gbahou F; El-Hady AK; Labani N; Schmidtkunz K; Boettcher S; Jockers R; Abdel-Halim M; Jung M; Zlotos DP
Arch Pharm (Weinheim); 2023 Sep; 356(9):e2300149. PubMed ID: 37339785
[TBL] [Abstract][Full Text] [Related]
37. The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.
Geurs S; Clarisse D; De Bosscher K; D'hooghe M
J Med Chem; 2023 Jun; 66(12):7698-7729. PubMed ID: 37276138
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors: a review on class-I specific inhibition.
Behera J; Jayaprakash V; Sinha BN
Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
[TBL] [Abstract][Full Text] [Related]
39. Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction network.
Sardiu ME; Smith KT; Groppe BD; Gilmore JM; Saraf A; Egidy R; Peak A; Seidel CW; Florens L; Workman JL; Washburn MP
Mol Cell Proteomics; 2014 Nov; 13(11):3114-25. PubMed ID: 25073741
[TBL] [Abstract][Full Text] [Related]
40. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
